Premium
PERCUTANEOUS IODINE‐125 SEED IMPLANTATION FOR CARCINOMA OF THE PROSTATE
Author(s) -
Kaye K. W.,
Olson D. J.,
Payne J. Thomas
Publication year - 1995
Publication title -
australian and new zealand journal of surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.111
H-Index - 51
eISSN - 1445-2197
pISSN - 0004-8682
DOI - 10.1111/j.1445-2197.1995.tb00676.x
Subject(s) - medicine , prostate , urology , percutaneous , brachytherapy , prostate specific antigen , adenocarcinoma , rectal examination , prostate carcinoma , biopsy , external beam radiotherapy , carcinoma , prostate biopsy , radiation therapy , surgery , oncology , cancer
This study was performed to assess the early results of treating stages T1‐T3 adenocarcinoma prostate with either Iodine‐125 ( 125 I) implant alone (Group 1), for smaller more well differentiated cancers, or with low dose external beam radiation followed by a 125 I boost (XRT + 125 I) (Group 2) for larger less well differentiated tumours. Eighty‐six patients were followed for between 11 and 60 months with a mean follow up of 26.1. All patients were followed by regular prostate specific antigen (PSA) evaluations, and digital rectal examinations (DRE). Eighty patients had a follow‐up biopsy at 1 year. Prostate specific antigen progression‐free survival (PSA‐PFS) was determined and defined. Complications and potency were also assessed. Early results of 125 I prostate seed implantation are very promising especially for selected cases of localized carcinoma.